Daily Endocrinology Research Analysis
Analyzed 21 papers and selected 3 impactful papers.
Summary
A controlled feeding RCT shows that altering the dietary carbohydrate-to-fat ratio drives consistent, reproducible shifts in plasma lipidomics, including triglyceride species linked to type 2 diabetes risk. A double-blind RCT finds that adding activated charcoal to febuxostat reduces gout flares and lowers LDL-C without additional urate-lowering. A large real-world cohort analysis associates GLP-1 receptor agonist therapy with improved overall survival after colorectal cancer diagnosis in patients with type 2 diabetes.
Research Themes
- Macronutrient ratio and metabolomic remodeling in cardiometabolic risk
- Adjunctive therapies for gout flares beyond urate lowering
- Oncologic outcomes associated with GLP-1 receptor agonists in diabetes
Selected Articles
1. Weight-independent effects of dietary carbohydrate-to-fat ratio on metabolomic profiles: secondary outcomes of a 5-month randomized controlled feeding trial.
In a controlled feeding RCT, varying the carbohydrate-to-fat ratio (CFR) produced consistent shifts in plasma lipidomics: plasmalogen classes and sphingomyelins decreased as CFR increased, while lysophospholipids and triglycerides rose. Eleven low–double-bond triglycerides linked to type 2 diabetes risk increased with higher CFR. Findings replicated in an independent feeding trial, suggesting mechanistic pathways by which macronutrient composition shapes metabolic risk.
Impact: This rigorously controlled trial demonstrates causal, weight-independent effects of macronutrient ratio on specific lipid pathways tied to diabetes risk, with replication enhancing credibility. It advances mechanistic nutrition science and identifies candidate biomarkers to guide dietary personalization.
Clinical Implications: Metabolomic signatures linked to dietary CFR could inform individualized macronutrient prescriptions for diabetes prevention and weight maintenance. Clinicians may consider monitoring lipidomic markers in research or specialized settings to tailor diet strategies.
Key Findings
- Dietary CFR was associated with changes in 148/479 metabolites at 20 weeks (FDR<0.05) with consistent trends at 10 and 20 weeks.
- Plasmalogen phosphatidylcholines/ethanolamines and sphingomyelins decreased with higher CFR, while lysophospholipids and triglycerides increased.
- Eleven triglyceride species with ≤3 double bonds, linked to type 2 diabetes risk, increased with higher CFR and results replicated in an independent feeding trial.
Methodological Strengths
- Controlled, parallel-group randomized feeding design with 20-week maintenance phase
- Targeted LC–MS/MS metabolomics and replication in an independent trial
Limitations
- Metabolomics were secondary outcomes; trial not powered for clinical endpoints
- Generalizability may be limited to adults with overweight/obesity in controlled feeding settings
Future Directions: Link diet-induced metabolomic shifts to hard clinical outcomes and test biomarker-guided macronutrient prescriptions in diverse populations.
Diet plays a crucial role in health, with low-carbohydrate diets often proposed to exert metabolic benefits. We aim to investigate metabolomic adaptations in 164 adults with overweight or obesity who were randomly assigned to high- (n = 54), moderate- (n = 53), or low-carbohydrate (n = 57) diets during a 20-week weight-loss maintenance phase of the Framingham State Food Study [(FS)2], a controlled, parallel feeding trial (ClinicalTrials.gov: NCT02068885). We measure fasting plasma metabolites by liquid chromatography-tandem mass spectrometry using samples from 147 participants who completed the study (n = 45, 48, and 54 in the high-, moderate-, and low-carbohydrate diet groups, respectively). Significant associations (False Discovery Rate<0.05) are identified between carbohydrate-to-fat ratio (CFR) and diet-induced changes in 148 of 479 metabolites at 20 weeks, with nearly all showing consistent trends at 10 and 20 weeks.
2. Efficacy and Safety of Activated Charcoal in Primary Gout: A Double-Blind, Double-Dummy, Randomized Controlled Trial.
Adding activated charcoal to febuxostat did not increase the proportion achieving serum urate <360 μmol/L but reduced gout flare frequency, delayed time to first flare, and lowered LDL-C at 24 weeks, with similar adverse event rates. This suggests a clinically meaningful, urate-independent benefit of AC as an adjunct in gout management.
Impact: This well-powered, double-blind RCT demonstrates reduced gout flares and improved lipid parameters with activated charcoal despite no additional urate lowering, challenging the assumption that flare reduction strictly tracks serum urate.
Clinical Implications: Activated charcoal may be considered as an adjunct to urate-lowering therapy to reduce flare burden during early treatment phases; clinicians should separate AC dosing from other oral medications to avoid adsorption-related interactions.
Key Findings
- No superiority of febuxostat plus activated charcoal on achieving serum urate <360 μmol/L versus febuxostat alone.
- Significant reductions in gout flare rates and delayed time to first flare with combination regimens compared with febuxostat 20 mg and 40 mg.
- Lower LDL-C at week 24 with combination therapy; adverse event rates were similar across groups.
Methodological Strengths
- Double-blind, double-dummy randomized design with four parallel arms
- Adequate sample size (n=348) and 24-week follow-up with predefined endpoints
Limitations
- Findings based on combination with febuxostat; effects of activated charcoal across other urate-lowering backbones remain to be established
- Mechanisms underlying flare reduction without additional urate lowering were not elucidated
Future Directions: Evaluate activated charcoal across different urate-lowering agents, explore dose–response and timing, and assess longer-term cardiovascular and renal outcomes.
BACKGROUND: Activated charcoal (AC), a known adsorbent in the gastrointestinal tract, has been reported to reduce serum urate (SU) levels. This study aimed to assess the efficacy and safety of AC in managing primary gout. METHODS: This double-blind, double-dummy, randomized controlled trial involved 348 patients, who were randomly assigned to one of four groups: febuxostat 40 mg, febuxostat 20 mg + AC 4.5 g, febuxostat 20 mg + AC 7.2 g, and febuxostat 20 mg. Patients were followed-up every 4 weeks until week 24. The primary endpoint was the proportion of patients achieving SU level < 360 μmol/L. RESULTS: All 348 enrolled patients were included in analysis. The febuxostat-AC combination regimen didn't demonstrate superior efficacy in controlling SU levels. However, the combination regimen significantly reduced flare rates compared to the febuxostat 20 mg group (≥ 1 and ≥ 3 flares, P < 0.05) and the febuxostat 40 mg group (≥ 1 flare, P < 0.05; ≥ 3 flares, P < 0.01), and it also significantly prolonged the time to first flare. Additionally, the combination regimen resulted in significantly lower low-density lipoprotein cholesterol (LDL-C) levels at week 24. The incidence of adverse events was similar across the groups.
3. Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study.
Among propensity-matched patients with type 2 diabetes and colorectal cancer (n=751 per group), GLP-1 receptor agonist use was associated with lower all-cause mortality (11.5% vs 20.4%; HR 0.58) and reduced metastasis risk (HR 0.60) over roughly two years, without increased major cardiovascular events.
Impact: This large real-world analysis supports the oncologic safety of GLP-1 RAs and suggests a potential survival benefit after colorectal cancer diagnosis, informing antidiabetic selection in oncology care.
Clinical Implications: For patients with type 2 diabetes undergoing treatment for colorectal cancer, GLP-1 RAs can be considered without apparent survival harm and may confer benefit; prospective trials are needed to confirm causality.
Key Findings
- After propensity score matching, 751 GLP-1 RA users were compared with 751 non-users; median follow-up ~2 years.
- All-cause mortality was lower in GLP-1 RA users (11.5% vs 20.4%; HR 0.58, 95% CI 0.45–0.76; P<0.001).
- Metastasis-free survival improved (HR 0.60, 95% CI 0.40–0.87; P=0.01), with no significant difference in MACE (HR 0.84; P=0.16).
Methodological Strengths
- Large, multi-institutional database with propensity score matching
- Time-to-event analyses using Kaplan–Meier and Cox models
Limitations
- Retrospective observational design susceptible to residual confounding and exposure misclassification
- Relatively short median follow-up (~2 years) limits assessment of long-term oncologic outcomes
Future Directions: Prospective, randomized studies and mechanistic investigations to determine causality and elucidate how GLP-1 signaling may impact colorectal cancer biology.
OBJECTIVES: To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP1-RA) use and all-cause mortality in patients with type 2 diabetes treated for colorectal cancer, using a real-world health database. METHODS: This retrospective cohort study was conducted using the TriNetX global health records network. Adult patients with type 2 diabetes diagnosed with colorectal cancer between 2010 and 2025 were included. Patients were divided into two cohorts based on GLP1-RA exposure versus other oral antidiabetic drugs. Propensity score matching was applied to balance covariates. Overall survival (primary outcome) and metastasis-free survival (secondary outcome) were analysed using Kaplan-Meier curves and Cox proportional hazards models. RESULTS: After propensity score matching, each cohort included 751 patients. Median follow-up period was 731 days in the GLP1-RA cohort and 779 days in the non-GLP1-RA cohort. GLP1-RA users had a significantly reduced all-cause mortality rate (11.5%) compared with non-users a (20.4%), with a hazard ratio of 0.58 (95%CI: 0.45-0.76; P < 0.001). Metastasis-free survival rate were 5.3% in the GLP1-RA cohort versus 8.9% in the matched non-user cohort, with a hazard ratio of 0.60 (95%CI: 0.40-0.87; P = 0.01). The incidence of major adverse cardiovascular events (MACE) did not differ significantly between cohorts, with a hazard ratio of 0.84 (95%CI: 0.66-1.06; P = 0.16). CONCLUSIONS: In this real-world cohort of diabetic patients treated for colorectal cancer, GLP1-RA therapy was associated with a significant improvement in overall survival. These findings support the continued use of GLP1-RA agents in this population and may provide reassurance to clinicians and patients regarding the safety and potential benefit of these agents following a colorectal cancer diagnosis.